Vandana Singh
·
September 5, 2025
Benzinga
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
read more
October 21, 2025
August 12, 2025
Bloomberg
August 6, 2025
Financial Times
August 1, 2025